On Apr. 21, 2020, Adamis Pharma announced that its wholly owned drug outsourcing facility, US Compounding (USC), has increased its product mix to provide additional drugs to assist in the ongoing fight against COVID-19. Due to this pandemic, the FDA allowed outsourcing facilities to compound certain medications that are in short supply, but not listed on FDAﾒs Drug Shortage List. USC has begun manufacturing a variety of these pharmaceutical products, many of which may be used to treat acutely ill COVID-19 patients.